|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | |  | | **Supplementary table. Demographic and clinical features of patients** | | | | | | | | |
| **No** | **Sex/**  **age** | **Sequence**  **& Timing** | | **Eyes**  **Attacks** | | **Disc Edema** | **Uveitis** | **Vision** | **NBD** | **VEP** | **FFA** | **Treatment** | **Recovery** |
| 1 | M/  37 | **ON🡪BD** (2 years) | | (RE) 1 | | Yes | N | (RE):1.0-0.0🡪0.70-0.0 |  | A |  | AZA+CS | Recovery |
| 2 | F/22 | **ON🡪BD**  (2 years) | | (LE) 1 | | Yes | Yes | (LE):0.0-0.70🡪0.0-0.40 |  |  |  | AZA+CS | Recovery |
| 3 | M/  27 | **BD🡪ON**  (1 year) | | (RE) 1 | | Yes | N | (RE): 0.60-0.0🡪0.20-0.0 | 1 year |  |  | AZA+CS | Recovery |
| 4 | F/25 | **ON🡪BD**  (2 years) | | (RE) 1  (LE) 1 | | No | N | LP-0.0 🡪 1.0-0.0 | NeuroBD |  |  | AZA |  |
| 5 | M/  41 | **BD🡪ON** (13 years) | | (RE) 1 | | Yes | Yes | LP-0.0; 1.0-0.0; | NeuroBD | A |  | AZA | No recovery |
| 6 | M/  32 | **ON🡪BD**  (ON=BD) | | (RE) 1 | | No | Yes | LP-0.0; 🡪0.0-0.0; | NeuroBD |  |  | AZA | Total recovery |
| 7 | M/  20 | **BD🡪ON**  (1 year) | | (RE) 1 | | Yes | Yes | (RE): 0.50-0.40🡪0.50-0.40; |  |  |  | CS | No recovery |
| 8 | M/  28 | **ON🡪BD**  (1 year) | | (RE) 1 | | Yes | Yes | (RE): 0.40-0.50🡪0.0-0. | NeuroBD| | A |  | AZA | Recovery |
| 9 | M/  55 | **BD🡪ON**  (6 years) | | (RE) 1 | | No | Yes | (RE): 0.40-1.0🡪 0.0-1.0;  (LE): amaurosis due to uveitis (NPL?) |  | A |  | AZA | Total recovery in RE |
| 10 | F/38 | **BD🡪ON** (2 years) | | (RE) 1  (LE) 2 | | No | (LE) | RE-LE; 0.50-0.10🡪0.0-0.0; |  | A |  | AZA+CS | Total recovery in both |
| 11 | M/  35 | **ON🡪BD**  (2 years) | | (RE): 2  (LE): 1 | | (LE): Yes | N | RE-LE; 1.0-0.50🡪0.1-0.0 |  |  |  | AZA+CS | Recovery in both |
| 12 | M/  40 | **BD🡪ON**  (1 year) | | (RE): 1 | | No | N | (RE): Finger count (CF ) 1m-0.0🡪0.50-0.0; |  | A |  | AZA+CS | Recovery |
| 13 | F/48 | **BD🡪ON**  (1 year) | | (LE) 1 | | Yes | Yes | (LE): 0.0-0.70🡪0.0-0.70; no recovery |  |  |  | AZA+CS | No recovery |
| 14 | F/55 | **BD🡪ON**  (8 years) | | (RE) 1  (LE) 2 | | (BE)  Yes | N | RE-LE; 1.0-1.0🡪0.2-1.0; |  |  |  | AZA+CS | Recovery in RE |
| 15 | F/37 | **ON🡪BD**  **(BD=ON)** | | (RE) 1  (LE) 2 | | Yes | N | RE-LE; 1.0-1.0🡪0.1-0.4; | NeuroBD |  |  | CTS+ CSA | Recovery in both |
| 16 | F/49 | **BD🡪ON**  (13 years) | | (LE) 1 | | No | N | (LE): 0.0-1.0🡪0.0-0.2; | NeuroBD |  |  | CS | Recovery |
| 17 | M/  27 | **ON🡪BD**  **(ON=BD)** | | (LE) 1 | | Yes | N | (LE): 0.0-1.0🡪0.0-0.1; |  |  |  | AZA+CS | Recovery |
| 18 | M/  42 | **BD🡪ON**  (9 years) | | (LE) 1 | | No | (LE) | (LE): 0.0-0.70🡪0.0-0.1; |  |  |  | AZA+CS | Recovery |
| 19 | M/  54 | **BD🡪ON** (14 years) | | (RE) 1  (LE) 1 | | (BE)  Yes | (LE) | (BON) 0.4-0.2🡪0.70-0.0; |  |  |  | AZA+ CS+ CSA | Recovery |
| 20 | F/34 | **BD🡪ON**  (10 years) | | (RE) 1 | | No | N | (RE):NA🡪 0.2-0.0 (final vision); |  |  |  | AZA+CS | Recovery |
| 21 | M/  38 | **ON🡪BD**  **(ON=BD)** | | (LE) 1 | | Yes | Yes | (LE): 0.0-1.0🡪0.0-0.2; |  |  |  | AZA+CS | Recovery |
| 22 | F/41 | **ON🡪BD**  **(ON=BD)** | | BON | | (BE)  Yes | Yes | Vision 0.5-0.2🡪0.0-0.0; |  |  |  | colchicine+ CTX+ CS | Total recovery |
| 23 | F/26 | **ON🡪BD**  **(ON=BD)** | | (RE) 3 | | Yes | yES | Vision 0.3-0.0🡪0.2-0.0; |  |  |  | AZA+CS+TNF | No recovery |
| 24 | F/16 | **ON🡪BD**  **(ON=BD)** | | BON | | (BE)  Yes | Yes | NA🡪 0.0-0.0; |  | N |  | Combined  (AZA+CS) | Total recovery |
| 25 | F/24 | **ON🡪BD**  **(ON=BD)** | | (LE) 2 | | Yes | N | (LE): 0.0-0.7🡪0.0-0.2; | NeuroBD | A |  | AZA+CS+ IFN | Recovery |

Features of patients diagnosed as optic neuritis associated with Behçet’s disease. Visual acuity has been represented in terms of logMar scale. Arrow between visual acuities represents transition from the first visual acuity to final visual acuity.

(A: Abnormal; AZA: Azathioprine; BD: Behçet’ disease; CS: Corticosteroids; ON:Optic neuropathy; R:Right; L:Left; RE: Right eye; LE: Left eye; BE: Bilateral eyes; EDSS:Expanded Disability Status Scale; OCB: Oligoclonal band; VEP: Visual evoked potential; FFA: Fundus fluorescein angiography; LP: Light perception; CF: Count finger)